Cannabidiol (CBD)

Articles

Hear a Noid Factoid from our latest podcast guest!

Noid Factoid from Podcast Episode 13

Lo Friesen is the founder, CEO, and Chief Extractor of Heylo. With a background in chemistry and clinical research, Lo was inspired to explore cannabis as a medicine and to enter the emerging industry. She joined Eden Labs, a leading CO

 extraction equipment manufacturer to support and expand a Research and Development department. There she managed the development of their latest and greatest CO

 extraction system. In 2017, after working with Eden Labs and another cannabis processor, Lo launched Heylo with a mission to help people get more out of life with cannabis.

In this article, we explore the difference in chemical profile between fresh and dry cannabis flower and why manufacturers may choose to extract frozen or dry cannabis.


The Transformation of Cannabis Terpenes from Harvest to Shelf

Recently, the University of Oxford began an international study to examine the potential therapeutic benefits of cannabidiol (CBD) in treating psychosis or psychotic symptoms.

Cannabidiol for Potentially Treating Psychosis: International Study Launched by University of Oxford

Cannabidiol (CBD) was recently studied in Mexico as a treatment for traumatic brain injury and Parkinson’s Disease.

Recent Studies from Medical Marijuana Inc. Test Cannabidiol for Treatment of Two Conditions

There goes another year in the books. This review of 2022’s extraction greatest hits takes a look at discoveries, advancements in technology, and other highlights from the year. This article also lays out some predictions for 2023, which is set up to be an interesting year with less access to funding that could slow the development of new technology or innovation in the extraction space.

Extraction 2022 Highlights and 2023 Predictions

A statement released on Thursday, January 26, 2023 from Dr. Janet Woodcock, the principal deputy commissioner of the Food and Drug Administration (FDA), announced that the FDA will work with Congress in formulating regulatory oversight to balance risk and access for products in the cannabidiol (CBD) market.

Food and Drug Administration to Work with Congress on Creating Regulatory Framework for the Cannabidiol Market

Currently in the life cycle of the cannabis industry, it is not obvious where the heavy metal regulatory landscape will end up. Clearly, the big four are not enough, but what is a realistic panel that reflects the real world of cannabinoid production?

Expanding the Panel of Heavy Metal Contaminants in Cannabis and Hemp Beyond the Big Four:  What Is the Regulatory Evidence Telling Us?

Recently, some major food and beverage companies expressed interest in selling products containing cannabidiol (CBD), but the Food and Drug Administration (FDA) have not indicated any regulatory progress.

Companies Want to Sell CBD Food and Beverages; Food and Drug Administration Gives Mixed Responses

A review of the claims that differences in extract type can affect cost, ease of formulation, and the experience of the finished product.

Does Extract Type Make  a Difference in Cannabis Edibles?

This article examines why we should be studying the cannabinoids beyond THC and CBD in order to explore their potential medical value.